Enthesopathy
Conditions
Keywords
Musculoskeletal Ultrasound, Psoriatic Arthritis, Enthesopathy
Brief summary
Psoriatic arthritis(PsA) and psoriasis(Ps) are two systemic inflammatory diseases linked with rash of psoriasis, but there's still great controversy regarding the exact relationship between them. Our study is to investigate the characteristics and differences of the ultrasonic imaging of enthesopathy in the lower extremity in patients with PsA and Ps, to explore the risk factors of Ps developing into PsA in the long term course.
Detailed description
As one of the most common chronic inflammatory skin diseases, psoriasis(Ps) can be intimately associated to psoriatic arthritis (PsA), affecting approximately 1% to 2% of the world's population. About 30% of them will develop into PsA with serious impact on their health-related quality of life. PsA, characterised by different subsets with varying degree of severity, is a chronic, complicated inflammatory disease.Enthesitis is the prevalent and distinctive feature of PsA. Musculoskeletal Ultrasound (MSUS) is a valid noninvasive modality, essential to evaluate entheses thickness, enthesophytes, bursitis and bone erosions as well as to disclose vascularisation on tendons through power doppler (PD) assessment. In recent years, more and more attention has been paid to the diagnosis and management of Ps and PsA, owing to its discrimination of identifying subclinical entheses and joint changes.
Interventions
Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
Sponsors
Chinese PLA General Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Clinical diagnosis of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis or osteoarthritis. * Body Mass Index (BMI)\<30 kg/m2. * Absence of local glucocorticoid or other drugs injection or surgical treatment for entheses scanned in the previous 6 weeks prior to clinical and musculoskeletal ultrasound (MSUS) evaluation.
Exclusion criteria
* Other systemic rheumatic diseases or malignant neoplasms. * Peripheral neuropathy of lower extremity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of enthesopathy comparison between psoriatic arthritis(PsA) and psoriasis(Ps) as assessed by SPSS v17.0 | up to 10 months |
Secondary
| Measure | Time frame |
|---|---|
| The potential risk factors of Ps for PsA as assessed by SPSS v17.0 | up to 10 months |
Countries
China
Contacts
Primary ContactFei Sun
Outcome results
None listed